PRESS RELEASE
Financial calendar for fiscal year 2017
Milan (Italy), January 30, 2017 - Please find here below the financial calendar of MolMed S.p.A. (MLM.MI) for fiscal year 2017. The calendar is available on MolMed's website (www.molmed.com). Any amendments will be promptly communicated to the market.
Board of Directors
DATE | SUBJECT |
6 MARCH 2017 | Approval of draft statutory financial statements for FY 2016 |
8 MAY 2017 | Approval of interim financial report at 31/03/2017(*) |
27 JULY 2017 | Approval of half-year financial report at 30/06/2017 |
6 NOVEMBER 2017 | Approval of interim financial report at 30/09/2017(*) |
(*) additional interim financial information
Shareholders' Meeting
DATE | SUBJECT |
10 APRIL 2017 | Approval of statutory financial statements for FY 2016 |
Under the new regulations in force1 and in order to ensure continuity with the past, MolMed decided to continue the publication of quarterly reports as additional interim financial information ("Additional Info"), on a voluntary basis and until otherwise decided, as already done during fiscal year 2016, with the same form and content to those of the previous fiscal years.
The Additional Info will be subject to approval by the Board of Directors (the "Board") in meetings to be held within 45 days from the end of the first and third quarter of each fiscal year, and will be disclosed to the market, again within 45 days from the end of the first and third quarter of each fiscal year, by means of:
issuance of a press release upon the conclusion of the Board meeting approving the interim financial information;
publication of the Additional Info on the corporate website (www.molmed.com) within the section devoted to financial reports.
This press release is written in compliance with public disclosure obligations established by Consob's (Italian securities & exchange commission) Issuers Regulation.
1 Italian Legislative Decree n. 25/2016 implementing Directive 2013/50/EU (the "Decree") eliminated the mandatory requirement to publish the quarterly interim financial reports, previously requested pursuant to paragraph 5, art.154-ter of Italian Legislative Decree n. 58/1998 (the "TUF"). The Decree also granted to Consob the powers of providing for any additional disclosure requirements beyond the annual and half- year financial statements. On the basis of the powers granted by the Decree, Consob - by way of resolution
n. 19770 of October 26, 2016 - introduced some amendments to the Issuers' Regulation concerning additional interim financial information (new Article 82-ter), in force from January 2, 2017.
FROM GENES TO THERAPYMOLMED S.p.A.
Via Olgettina, 58 - 20132 Milan, Italy | Phone +39 02 21277.1 - Fax +39 02 21277.325 info@molmed.com - www.molmed.com
Share capital € 19,841,682.30 fully paid - Office of Milan Company Registry number 1506630 - Tax identification number 11887610159
COMUNICATO STAMPA
About MolMed
MolMed S.p.A. is a medical biotechnology company focused on research, development and clinical validation of novel anticancer therapies. MolMed's pipeline includes anti-tumour therapeutics in clinical and preclinical development: Zalmoxis® (TK) is a cell-based therapy enabling bone marrow transplants from partially compatible donors, in absence of post-transplant immune-suppression prophylaxis, currently in Phase III in high-risk acute leukaemia and granted a Conditional Marketing Authorisation by the European Commission; NGR-hTNF is a novel therapeutic agent for solid tumours which displays antitumor activity through its specific binding to blood vessels feeding the cancer and to the concentration of immune system cells into the tumour mass, currently investigated in a broad clinical programme, involving more than 1000 treated patients; CAR- CD44v6 is an immune gene therapy project potentially effective for many haematological malignancies and several epithelial tumours, currently in preclinical development. MolMed also offers top-level expertise in cell and gene therapy to third parties to develop, conduct and validate projects from preclinical to Phase III trials, including scale-up and cGMP manufacturing of viral vectors and patient-specific genetically engineered cells. MolMed is headquartered at the San Raffaele Biotechnology Department (DIBIT) in Milan, Italy, and has an operating unit at OpenZone in Bresso (Milan, Italy). MolMed is listed on the main market (MTA) of the Milan stock exchange managed by Borsa Italiana (ticker Reuters: MLMD.MI).
For further information:
Laura Villa
Investor Relations & Communication Director
MolMed S.p.A.
phone: +39 02 21277.205
fax: +39 02 21277.325
e-mail: investor.relations@molmed.com
Andrea Quaglino
Administration, Finance & Control Director
MolMed S.p.A.
phone: +39 02 21277.302
fax: +39 02 21277.404
e-mail: afc@molmed.com
FROM GENES TO THERAPY2
MolMed S.p.A. published this content on 30 January 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 30 January 2017 15:54:19 UTC.
Original documenthttp://www.molmed.com/node/3060?language=en
Public permalinkhttp://www.publicnow.com/view/E25C8DDBA9AD75CDCFF1C1FFF2FBD0811504406A